Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Ya-Yen Yu, Shih-Ming Tsao, Wen-Ta Yang, Wei-Chang Huang, Ching-Hsiung Lin, Wei-Wen Chen, Shun-Fa Yang, Hui-Ling Chiou and Yi-Wen Huang
Additional contact information
Ya-Yen Yu: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shih-Ming Tsao: Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan
Wen-Ta Yang: Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan
Wei-Chang Huang: Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan
Ching-Hsiung Lin: Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan
Wei-Wen Chen: Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Hui-Ling Chiou: School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan
Yi-Wen Huang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2019, vol. 17, issue 1, 1-9

Abstract: Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015–4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022–2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250–2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.

Keywords: drug metabolic enzymes; polymorphism; latent tuberculosis; adverse drug reaction (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/1/210/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/1/210/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2019:i:1:p:210-:d:302628

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().